Previous Page
20
nanotimes
Companies Facts
ment for a joint offering to the life sciences industry. Proteros, an expert in the field of protein crystalliza- tion and X-ray structural analysis, provides services that complement AMRI’s existing drug discovery capabilities in chemistry, in vitro biology, drug meta- bolism and pharmacokinetics services.
pany Antisense Pharma presented current data from its ongoing clinical Phase I/II trial with intrave- nous monotherapy of trabedersen (AP 12009) for the treatment of patients with advanced pancreatic cancer (PanCa), malignant melanoma (MM), and colorectal carcinoma (CRC). During the oral presen- tation session ‘Developmental Therapeutics – Clinical Pharmacology and Immunotherapy’ Helmut Oettle, MD, PhD, Charité Medical Faculty of the Humboldt University of Berlin, coordinating investigator pointed out trabedersen’s encouraging safety and efficacy data: “These data suggest that trabedersen is safe and very well tolerated in systemic application – and quality of life is already a crucial factor in validation of new anti cancer drugs.” PanCa patients treated 2 nd-line with trabedersen (N=15) reached a median overall survival (mOS) of 6.9 months which is com- parable to best available chemotherapy (mOS 5 – 6 months, historical data) 1. Additionally, patients treated 2nd-line with the dose 140 mg/m2/d (N=9) showed an encouraging survival benefit: their mOS was 13.4 months – in comparison to best available chemotherapy.
A
t the international cancer congress ASCO 2011 in Chicago, USA, the biopharmaceutical com-
MRI (NASDAQ: AMRI) and Proteros Biostruc- tures GmbH (Proteros) have signed an agree-
“Since there is no approved 2nd-line treatment for PanCa patients in the USA and Europe, we are con- fident that our innovative immunostimulatory me- dication trabedersen will help to prolong survival in advanced pancreatic cancer patients.” adds Hubert Heinrichs, MD, PhD, Chief Medical Officer at Anti- sense Pharma.
http://www.antisense-pharma.com http://chicago2011.asco.org/Home.aspx http://abstract.asco.org/AbstView_102_74007.html
Commission for a proposed initial public offering of its common stock. Goldman, Sachs & Co. and Mor- gan Stanley & Co. LLC will act as joint book-running managers for the offering. The number of shares to be sold in the proposed offering and the price range of the proposed offering have not yet been deter- mined.
A
In October 2011, BASF Venture Capital, Germany, has led a $21.5 million round of investment in Aspen Aerogels, Inc. Aspen supplies reinforced, nanopo- rous aerogel insulation products that are up to five times more effective than other insulation mate- rials. The company‘s solutions enable customers to conserve energy in a variety of industries including building and construction, chemicals, transportation and oil and gas.
Other investors are RockPort Capital, Tenaya Ca- pital, Reservoir Capital Group, Arcapita Ventures
spen Aerogels, Inc., has filed a registration statement with the Securities and Exchange
11-06/07 :: June/July 2011